PeptidePros
All Peptides

Thymosin Alpha-1

Also known as Thymalfasin · Tα1

Immunomodulatory peptide approved in various countries with broader clinical literature than most RUO peptides.

Tier Bmedium riskintermediate
Tier B
Evidence
4-8 week phase
Protocol
medium
Risk
subcut.
Route

Jurisdiction Dependent

Regulatory status for this substance varies by country and jurisdiction. Check local regulations before any procurement or research use.

Evidence visual

Thymosin Alpha-1 evidence and risk matrix

intermediate researcher fit

Evidence

Tier B

Risk

medium

Regulatory

investigational

WADA

none

FDA

unknown

Route

subcutaneous

Higher-confidence evidence profile, but regulatory and sourcing checks still matter.

Overview

Thymosin alpha-1 (thymalfasin) is an immunomodulatory peptide influencing innate and adaptive pathways. Reviews describe immune-restoring effects and use as immune enhancer in viral infections and other contexts. Approved in various countries; US regulatory status differs. Generally discussed as tolerable in clinical contexts but still requires clinician oversight. Better suited to clinician-referral ecosystems than pure RUO e-commerce.

Decision path

Where Thymosin Alpha-1 fits in the research path.

Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.

2 related goals
  1. 01

    Read evidence

  2. 02

    Check risk

  3. 03

    Compare options

  4. 04

    Build plan

Peptide research path

Decide whether Thymosin Alpha-1 belongs in your plan.

Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.

Research Details

Mechanism of Action

Immunomodulatory peptide influencing innate/adaptive immune pathways; immune-restoring effects described.

Administration Routes

subcutaneous

Study Dose Range

Condition-specific dosing in clinical practice; varies by jurisdiction.

Expected Effects

Immune modulation; clinical literature broader than most RUO peptides.

Dosing Timeline

Immune biomarkers and clinical outcomes over weeks to months.

Contraindications

Potential interactions with immunotherapies/vaccines.

Adverse Effects

Generally tolerable in clinical contexts; clinician oversight required.

Interaction Notes

Potential interactions with immunotherapies/vaccines; do not provide combination advice.

Cost at a glance

Typical cycle cost

$79.98

Estimated monthly

$53.32

Protocol style

4-8 week phase

Phase-based

Estimate confidence

High confidence

Assumes roughly 10 mg20 mg per cycle, using 1 tracked affiliated listing.

Reflects multi-week immune support blocks rather than daily indefinite use.

Age, sex, and monitoring

Life-stage fit

Age fit improves later in life because immune-support logic becomes more relevant as immunosenescence rises.

35-4445-5455-6465+

Best fit age ranges: 55-64, 65+

Sex-specific note

Immune-support framing is broadly sex-neutral based on the current evidence.

femalemaleother

female

Pregnancy and lactation caution remains reasonable because the evidence base is not built around those contexts.

Monitoring burden

medium

Immune-support framing still deserves a clean baseline and a more cautious read in autoimmune or cancer-sensitive contexts.

Baseline labs and checks

CBC, CMP, clinical review of immune history

Follow-up cadence

Periodic reassessment every few months, especially if health context is complex.

Red flags

  • hypersensitivity reactions
  • unexpected immune flares
  • new inflammatory symptoms

Frequently Compared

Compare top

Thymosin Beta-4

Tier B-C

MOTS-c

Tier C

Epitalon

Tier C-D

FOXO4-DRI

Tier C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Personalized peptide routing

Find the right path for Thymosin Alpha-1.

Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.

  • Goal-matched compound and protocol recommendations.
  • Budget and sourcing filters before you leave the site.
  • PDF unlocks shown after your personalized result.
Take the quiz